Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmatrix (PULM) Gains from Sales and Divestitures (2016 - 2017)

Pulmatrix's Gains from Sales and Divestitures history spans 3 years, with the latest figure at $5187.0 for Q4 2017.

  • For Q4 2017, Gains from Sales and Divestitures fell 95.04% year-over-year to $5187.0; the TTM value through Dec 2017 reached $5187.0, down 95.04%, while the annual FY2017 figure was $5187.0, 95.04% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2017 was $5187.0 at Pulmatrix, down from $104495.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $180090.0 in Q3 2015 and bottomed at $5187.0 in Q4 2017.
  • The 3-year median for Gains from Sales and Divestitures is $99309.0 (2015), against an average of $95496.9.
  • The largest annual shift saw Gains from Sales and Divestitures rose 5.22% in 2016 before it plummeted 95.04% in 2017.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $99309.0 in 2015, then grew by 5.22% to $104495.0 in 2016, then tumbled by 95.04% to $5187.0 in 2017.
  • Per Business Quant, the three most recent readings for PULM's Gains from Sales and Divestitures are $5187.0 (Q4 2017), $104495.0 (Q4 2016), and $99308.0 (Q2 2016).